Global Crigler–Najjar Syndrome Market By Treatment (Medication, Surgery), Drugs (Bilirubin Chelators, Ursodeoxycholic Acid and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others)
Market Definition: Global Crigler–Najjar Syndrome Market
Crigler–Najjar syndrome is rare genetic liver disorder characterized by abnormal accumulation of bilirubin, a yellow pigment produced by the liver. This accumulation is caused by deficiency of the enzyme called UGT1A1. This enzyme is responsible for the conversion of bilirubin into a substance that can be eliminated. Crigler–Najjar Syndrome can cause significant neurological damage.
According to the statistics published in the U.S. Department of Health & Human Services, an estimated annual prevalence of Crigler-Najjar syndrome is 1 in one million newborns worldwide. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth
Request Sample Report at @
- Huge financial support to the researchers for developing novel intervention is boosting the market growth
- Increase in demand of disease specific novel treatment can also act as a market driver
- Family history of Crigler–Najjar syndrome is driving the growth of the market
- Increase in special designation from the regulatory authorities is drive the market
- Lack of healthcare budget in some middle-income countries is restraining the market growth
- Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
Get ToC @
Market Analysis: Global Crigler–Najjar Syndrome Market
Global Crigler–Najjar syndrome market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market.
Segmentation: Global Crigler–Najjar Syndrome Market
- Bilirubin Chelators
- Ursodeoxycholic Acid
By Route of Administration
By End Users
- Specialty Clinics
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
Key Developments in the Market:
In February 2018, Audentes Therapeutics has initiated a first dose of patients in VALENS, a Phase I/II clinical trial of AT342, a gene therapy for the treatment of Crigler-Najjar Syndrome. AT342 has received Rare Pediatric Disease and Fast Track designations from the FDA. These designations provide significant benefits to the company including opportunities to work with the FDA to expedite the development of AT342.
Global Crigler–Najjar syndrome market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global Crigler–Najjar syndrome market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research